HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT
0.0.1 - DRAFT
HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT
0.0.1 - DRAFT
HL7 FHIR Implementation Guide: Common Terminology Criteria (CTC) Adverse Events Release 1 - DRAFT, published by HL7 International Clinical Interoperability Council. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/standardhealth/fsh-ae/ and changes regularly. See the Directory of published versions
Generated Narrative: MedicationRequest
Resource MedicationRequest "cancer-related-medication-request-doxorubicin2-persona-2"
Profile: Cancer-Related Medication Request
Treatment Intent: Curative - procedure intent (qualifier value) (SNOMED CT#373808002)
status: on-hold
intent: order
category: Outpatient (MedicationRequest Category Codes#outpatient)
medication: DOXOrubicin (RxNorm#3639)
subject: Patient/PatientPersona2 " C."
authoredOn: 2020-12-21
requester: Practitioner/us-core-practitioner-owen-oncologist " ONCOLOGIST"
reasonReference: Condition/primary-cancer-condition-persona-2
dosageInstruction
text: doxorubicin (60 mg/m² IV)
timing: Starting 2020-10-25, Once
route: Intravenous route (qualifier value) (SNOMED CT#47625008)
doseAndRate
maxDosePerPeriod: 1/3 week (Details: UCUM code wk = 'wk')